ESMO
ESMO Introduces New Framework for Evaluating Tumor-Agnostic Potential of Cancer Treatments
2024-09-03
Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022
2022-09-13
Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line(1L)treatment for NSCLC at ESMO 2022
2022-09-13
Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022
2022-09-12
ESMO 2022 – Great oaks grow from small acorns: oncology is committed to doing its part for sustainability
2022-09-09
Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022
2022-09-08
Bispecific Antibodies or CAR T-Cells: Which One of These Cancer Immunotherapies Would Prevail?
2021-09-29
ESMO21: Latest Clinical Studies Answer Central Questions in the Treatment of Leading Cancers
2021-09-22
LATEST
Crossing Borders for a New Era in Healthcare Quality: Highlights from the 1st Asia Pacific Forum on Healthcare Quality
2024-12-12
Precision Medicine in Breast & Lung Cancer: Coordinated Diagnostics and Treatment Approaches for Personalized Care
2024-12-12
Fighting the Good Fight: Global Experts Unite to Share Oncology Breakthroughs at Asia-Pacific Precision Cancer Treatment Forum
2024-12-12